I made sure in both cases that Merck had an opportunity to read my analysis. As of fall 2006, the AIDS vaccine had yet to see the light of day.
My helpful input may have been a factor.
But, at the same time, that incident probably branded me as a troublemaker as far as that company was concerned. Thus, in June 2006, they didn't seem to be interested in learning anything more about my thinking. Indeed, in that month I was informed by Merck media relations that they were sorry, but they simply couldn't respond to what I was saying about their cervical cancer vaccine.
That was because no one at Merck was able to access this web site.
And they were unable to access this web site because of a "firewall" which their own company had installed to try to make it impossible for anyone there to receive my site. (Of course, they could still receive it on computers in their homes or in libraries open to the public.)
Continue
Tom F. Hrisomalos, Denise L. Boggs, and Kenneth H. Fife; Journal of Virology, October 1990, page 5188.
The best way to find this reference may be through bound journal copies in the libraries of larger universities and medical schools. Kenneth Fife was on the faculty of the Indiana University Medical School in Indianapolis at the time of this writing.